{"grounding": "Shortly after the emergence of coronavirus disease 2019 (COVID-19) in late 2019, clinicians rapidly recognized an apparent association between the disease and both arterial and venous thrombotic complications, which was confirmed in epidemiologic studies. Based on these data, hospitals empirically developed and implemented protocols with different strategies for anticoagulation of hospitalized COVID-19 patients. Subsequent randomized controlled trials (RCTs) clarified the role of anticoagulation in patients hospitalized with COVID-19 and recently discharged from the hospital. In this review, we discuss the epidemiology and pathophysiology of thrombosis in patients with COVID-19, observational comparative effectiveness analyses that provided hints of a benefit from anticoagulation, and finally the RCTs that established which patients with COVID-19 benefit from treatment-dose anticoagulation. These RCTs have demonstrated that hospitalized, noncritically ill patients with COVID-19 benefit from treatment-dose anticoagulation, but patients who are hospitalized and critically ill, discharged from the hospital, or not hospitalized do not benefit.", "generated_text": "The COVID-19 pandemic has been associated with a significant increase in thrombotic complications, posing a challenge to healthcare systems worldwide. This study explores the pathophysiological mechanisms underlying COVID-19-associated thrombosis, emphasizing the role of endothelial dysfunction, hypercoagulability, and platelet activation. The review synthesizes current evidence on the efficacy and safety of anticoagulants and platelet aggregation inhibitors in managing these complications. Anticoagulants, such as heparin and direct oral anticoagulants, have shown promise in reducing thrombotic events, while platelet aggregation inhibitors like aspirin may offer additional benefits in specific patient populations. However, the optimal therapeutic strategy remains uncertain, necessitating further clinical trials to refine treatment protocols. This paper highlights the importance of individualized patient assessment and the potential for combination therapies to mitigate the risk of thrombosis in COVID-19 patients. Understanding these therapeutic strategies is crucial for improving patient outcomes and guiding future research in this evolving field.", "label": 1}